These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25655720)

  • 21. PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain.
    Nordstrom AL; Mansson M; Jovanovic H; Karlsson P; Halldin C; Farde L; Vanover KE; Hacksell U; Brann MR; Davis RE; Weiner DM
    Int J Neuropsychopharmacol; 2008 Mar; 11(2):163-71. PubMed ID: 17708779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5‑Hydroxytryptamine 2A receptor inverse agonist pimavanserin impairs maternal behavior in postpartum female rats.
    Gan L; Sun M; Chen W
    Pharmacol Biochem Behav; 2018 Dec; 175():152-159. PubMed ID: 30393120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis, radiofluorination, and preliminary evaluation of the potential 5-HT
    Edgar FG; Hansen HD; Leth-Petersen S; Ettrup A; Kristensen JL; Knudsen GM; Herth MM
    J Labelled Comp Radiopharm; 2017 Oct; 60(12):586-591. PubMed ID: 28856700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct comparison of [(18) F]MH.MZ and [(18) F] altanserin for 5-HT2A receptor imaging with PET.
    Hansen HD; Ettrup A; Herth MM; Dyssegaard A; Ratner C; Gillings N; Knudsen GM
    Synapse; 2013 Jun; 67(6):328-37. PubMed ID: 23390031
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Petersen IN; Villadsen J; Hansen HD; Madsen J; Jensen AA; Gillings N; Lehel S; Herth MM; Knudsen GM; Kristensen JL
    Org Biomol Chem; 2017 May; 15(20):4351-4358. PubMed ID: 28474719
    [No Abstract]   [Full Text] [Related]  

  • 26. Pimavanserin: An Inverse Agonist Antipsychotic Drug.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2016 Jun; 54(6):21-4. PubMed ID: 27245248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiosynthesis and in vivo evaluation of novel radioligands for PET imaging of cerebral 5-HT7 receptors.
    Hansen HD; Herth MM; Ettrup A; Andersen VL; Lehel S; Dyssegaard A; Kristensen JL; Knudsen GM
    J Nucl Med; 2014 Apr; 55(4):640-6. PubMed ID: 24566002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of 7-day repeated treatment with the 5-HT2A inverse agonist/antagonist pimavanserin on methamphetamine vs. food choice in male rhesus monkeys.
    Banks ML
    Drug Alcohol Depend; 2016 Aug; 165():260-4. PubMed ID: 27242287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and in vitro evaluation of [18F]FECIMBI-36: A potential agonist PET ligand for 5-HT2A/2C receptors.
    Prabhakaran J; Underwood MD; Kumar JS; Simpson NR; Kassir SA; Bakalian MJ; Mann JJ; Arango V
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3933-6. PubMed ID: 26253634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis.
    Isaacson SH; Coate B; Norton J; Stankovic S
    J Parkinsons Dis; 2020; 10(4):1389-1396. PubMed ID: 32716320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders.
    Abbas A; Roth BL
    Expert Opin Pharmacother; 2008 Dec; 9(18):3251-9. PubMed ID: 19040345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pimavanserin: First Global Approval.
    Markham A
    Drugs; 2016 Jul; 76(10):1053-7. PubMed ID: 27262680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
    Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
    Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Chendo I; Ferreira JJ
    Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
    Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiosynthesis and preclinical evaluation of 18F-F13714 as a fluorinated 5-HT1A receptor agonist radioligand for PET neuroimaging.
    Lemoine L; Becker G; Vacher B; Billard T; Lancelot S; Newman-Tancredi A; Zimmer L
    J Nucl Med; 2012 Jun; 53(6):969-76. PubMed ID: 22577236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT
    Ma M; Yang Y; Du G; Dai Y; Zhu X; Wang W; Xu H; Zhang J; Zheng L; Zou F; Yang H; Liu B; Liu W; Ye L; Zhang R; Tian J
    Eur J Med Chem; 2022 Apr; 234():114246. PubMed ID: 35279606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pimavanserin use in a movement disorders clinic: a single-center experience.
    Mahajan A; Bulica B; Ahmad A; Kaminski P; LeWitt P; Taylor D; Krstevska S; Patel N
    Neurol Sci; 2018 Oct; 39(10):1767-1771. PubMed ID: 30032332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis.
    Patel N; LeWitt P; Neikrug AB; Kesslak P; Coate B; Ancoli-Israel S
    Clin Neuropharmacol; 2018; 41(6):210-215. PubMed ID: 30303817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of stress on gill basolateral membrane binding kinetics of 5-ht2 receptor ligands: potential implications for urea excretion mechanisms.
    Frere AW; McDonald MD
    J Exp Zool A Ecol Genet Physiol; 2013 Jun; 319(5):237-48. PubMed ID: 23495168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.